Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas

Learn more about:
Related Clinical Trial
A Phase 1, Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell and Indolent B-Cell Lymphomas Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas AMG 319 Lymphoid Malignancy FIH Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies Tandem Auto-Allo Transplant for Lymphoma Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas CD4CAR for CD4+ Leukemia and Lymphoma Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma A Study for Patients With Non-Hodgkin’s Lymphomas High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma Allo-HSCT as First-line Consolidation in High-risk PTCL A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low ( T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia A Multicenter Clinical Trial of Daratumumab in Combination With Gemcitabine, Dexamethasone and Cisplatin in Patients With Relapsed/Refractory CD38 Positive PTCL-NOS, Angioimmunoblastic T-cell Lymphoma AITL and Other Nodal Lymphomas of T Follicular Helper Cells Origin Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin’s Lymphoma HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma Gemcitabine in NK/T Cell Lymphoma A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma Trial of Endostar Combined With CHOPT for T Cell Lymphoma Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Brief Title

Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas

Official Title

Open-Label, One Arm Pilot Investigation of Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas

Brief Summary

      The purpose of this study is to:

        -  assess the effectiveness of lenalidomide for the treatment of patients with relapsed and
           or refractory peripheral T-cell lymphomas; and,

        -  assess the safety of lenalidomide.

      There are reports suggesting a therapeutic benefit of thalidomide in patients with refractory
      and/or relapsed Non-Hodgkin's Lymphoma's (NHL) which have led to the formal investigation of
      lenalidomide in the treatment of relapsed NHL's.

Detailed Description

      Peripheral T-cell lymphomas (PTCL's) represent a subgroup of Non-Hodgkin's lymphomas with
      poor prognostic features. Compared to aggressive B-cell lymphomas, PTCL's often present with
      more advanced disease and sustain less durable remissions following treatment with
      chemotherapy. With standard anthracycline-based regimens such as CHOP (cyclophosphamide,
      doxorubicin, vincristine, prednisone), PTCLs achieve inferior 5-year overall survival rates
      of around 40% compared to aggressive B-cell lymphomas whose 5-year overall survival rates
      reach 50-60%. While several salvage regimens have been established for B-cell lymphomas with
      moderate success, the guidelines for patients with relapsed and/or refractory PTCL's are less
      clear. Several reports suggest that the immunomodulatory drugs (IMiDs®) have clinical
      activity in this setting. The aim of this phase 2 study is to evaluate the activity of
      lenalidomide in relapsed and/or refractory PTCL's.

Study Phase

Early Phase 1

Study Type


Primary Outcome

Response Rate to lenalidomide (CR,PR and unconfirmed complete responses

Secondary Outcome

 Toxicity of lenalidomide


Peripheral T-cell Lymphomas



Study Arms / Comparison Groups



* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

June 2008

Completion Date

December 2009

Primary Completion Date

July 2009

Eligibility Criteria

        Inclusion Criteria:

          1. Understand and voluntarily sign an informed consent form.

          2. Age 19 and over at the time of signing the informed consent form.

          3. Able to adhere to the study visit schedule and other protocol requirements.

          4. Patients with a confirmed diagnosis of peripheral T-cell lymphomas according to the
             World Health Organization (WHO) classification in the relapsed and/or refractory
             setting following prior anthracycline therapy. Subtypes of peripheral T-cell lymphomas
             which meet this criteria will include the following: adult T-cell leukemia/lymphoma,
             peripheral T-cell lymphoma unspecified, angioimmunoblastic T-cell lymphoma, anaplastic
             large-cell lymphoma, T/null cell, primary systemic type, subcutaneous
             panniculitis-like T-cell lymphoma, hepatosplenic gamma-delta T-cell lymphoma, and
             enteropathy-type T-cell lymphoma [33].

          5. Patients with a history of PTCL or cutaneous T-cell lymphoma (CTCL) with
             nodal/visceral disease in the relapsed and/or refractory setting following prior
             anthracycline therapy. This includes ≥ 3-6 cycles of CHOP (cyclophosphamide,
             doxorubicin, vincristine, prednisone) or an equivalent, CHOP-like regimen +/-
             radiation therapy. The definition for relapsed and refractory disease is provided in
             Appendix 5.

          6. All previous cancer therapy, including radiation, hormonal therapy and surgery, must
             have been discontinued at least 4 weeks prior to treatment in this study.

          7. At least one measurable lesion according to the International Working Group response
             criteria for non-Hodgkin's lymphoma (see Appendix 5).

          8. ECOG performance status of less than or equal to 2 at study entry (see Appendix 2).

          9. Laboratory test results within these ranges:

               -  Absolute neutrophil count greater than or equal to 1.5 x 109/L

               -  Platelet count greater than or equal to 100 x 109/L (>70 x 10^9/L if bone marrow
                  was involved)

               -  Serum creatinine less than or equal to 2.0 mg/dL

               -  Total bilirubin less than or equal to 1.5 mg/dL

               -  AST (SGOT) and ALT (SGPT) less than or equal to 2 x upper limit of normal (ULN)
                  or less than or equal to 5 x ULN if hepatic metastases are present.

         10. Females of childbearing potential (FCBP)† must have a negative serum or urine
             pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
             therapy and again within 24 hours of prescribing lenalidomide and must either commit
             to continued abstinence from heterosexual intercourse or begin TWO acceptable methods
             of birth control, one highly effective method and one additional effective method AT
             THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also
             agree to ongoing pregnancy testing. Men must agree to use a latex* condom during
             sexual contact with a FCBP even if they have had a successful vasectomy. All patients
             must be counseled at a minimum of every 28 days about pregnancy precautions and risks
             of fetal exposure. See Appendix 1: Risks of Fetal Exposure, Pregnancy Testing
             Guidelines and Acceptable Birth Control Methods.

             * For patients who have latex allergies or whose partner(s) have latex allergies
             alternatives will be discussed.

         11. All study participants must be registered into the mandatory RevAssist® program, and
             be willing and able to comply with the requirements of RevAssist®.

         12. Disease free of prior malignancies for greater than or equal to 5 years with exception
             of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma
             "insitu" of the cervix or breast

         13. Able to take aspirin (81 mg) daily as prophylactic anticoagulation, if deemed
             necessary by investigator (patients intolerant to ASA may use warfarin or low
             molecular weight heparin).

        Exclusion Criteria:

          1. Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          2. Pregnant or breast feeding females. (Lactating females must agree not to breast feed
             while taking lenalidomide).

          3. Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study.

          4. Use of any other experimental drug or therapy within 28 days of baseline.

          5. Known hypersensitivity to thalidomide.

          6. The development of erythema nodorum if characterized by a desquamating rash while
             taking thalidomide or similar drugs.

          7. Any prior use of lenalidomide.

          8. Concurrent use of other anti-cancer agents or treatments within the past 28 days.

          9. Known positive for HIV or infectious hepatitis, type A, B or C.

         10. (Other) Precursor T-cell lymphomas (including immature T-cell lymphomas/leukemias) and
             cutaneous T-cell lymphomas (CTCL) with skin as the only organ of involvement

         11. Patients with prolonged QT interval on baseline EKG (>430 ms)

         12. Equal to greater than grade 3 peripheral neuropathy.

         13. Natural Killer (NK) cell lymphomas




19 Years - N/A

Accepts Healthy Volunteers



James Foran, M.D., , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs

UAB 0663

Responsible Party


Study Sponsor

University of Alabama at Birmingham

Study Sponsor

James Foran, M.D., Principal Investigator, University of Alabama at Birmingham

Verification Date

April 2012